scholarly journals Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study

2016 ◽  
Vol 16 (4) ◽  
pp. 256-261 ◽  
Author(s):  
Kari B. Wisinski ◽  
Wei Xu ◽  
Amye J. Tevaarwerk ◽  
Sandeep Saha ◽  
KyungMann Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Estrogen Receptor Beta ◽  
High Dose ◽  
Phase 2 ◽  
Phase 2 Study ◽  
Receptor Beta

scholarly journals Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer

Cells ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. 874 ◽  
Author(s):  
Elena Alexandrova ◽  
Jessica Lamberti ◽  
Pasquale Saggese ◽  
Giovanni Pecoraro ◽  
Domenico Memoli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cell Lines ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Cholesterol Biosynthesis ◽  
Regulation Of Gene Expression ◽  
Estrogen Receptor Beta ◽  
Tyrosine Kinase 2 ◽  
Receptor Beta

Triple-negative breast cancer (TNBC) is a highly heterogeneous disease, representing the most aggressive breast cancer (BC) subtype with limited treatment options due to a lack of estrogen receptor alpha (ERα), progesterone receptor (PR), and Erb-B2 receptor tyrosine kinase 2 (HER2/neu) expression. Estrogen receptor beta (ERβ) is present in a fraction of TNBC patients, where its expression correlates with improved patient outcomes, supported by the fact that it exerts oncosuppressive effects in TNBC cell models in vitro. ERβ is involved in microRNA-mediated regulation of gene expression in hormone-responsive BC cells and could mediate its actions through small noncoding RNAs (sncRNAs) in TNBCs also. To verify this possibility, smallRNA sequencing was performed on three ERβ-expressing cell lines from different TNBC molecular subtypes. Several sncRNAs resulted modulated by ERβ, with a subset being regulated in a tumor subtype-independent manner. Interestingly, sncRNA profiling of 12 ERβ+and 32 ERβ− primary TNBC biopsies identified 7 microRNAs, 1 PIWI-interacting RNA (piRNA), and 1 transfer RNA (tRNA) differentially expressed in ERβ+ compared to ERβ− tumors and cell lines. Among them, miR-181a-5p was found to be overexpressed in ERβ+ tumors and predicted target key components of the cholesterol biosynthesis pathway previously found to be inhibited by ERβ in TNBC cells.

scholarly journals Estrogen receptor-beta is a potential target for triple negative breast cancer treatment

Oncotarget ◽  
2018 ◽  
Vol 9 (74) ◽  
pp. 33912-33930 ◽  
Author(s):  
David Austin ◽  
Nalo Hamilton ◽  
Yahya Elshimali ◽  
Richard Pietras ◽  
Yanyuan Wu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Treatment ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Estrogen Receptor Beta ◽  
Breast Cancer Treatment ◽  
Potential Target ◽  
Receptor Beta

Abstract PS18-39: Estrogen receptor beta agonists for triple negative breast cancer

2021 ◽  
Author(s):  
Jharna Datta ◽  
Natalie Willingham ◽  
Jasmine Manouchehri ◽  
Joel David ◽  
Mirisha Sheth ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Estrogen Receptor Beta ◽  
Beta Agonists ◽  
Receptor Beta
Sign in / Sign up

Export Citation Format

Share Document